154 related articles for article (PubMed ID: 7907906)
21. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
22. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
23. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
24. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
26. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M; Al-Kgodary T
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[TBL] [Abstract][Full Text] [Related]
28. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
29. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
31. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
32. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
33. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
[TBL] [Abstract][Full Text] [Related]
34. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK
Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
[TBL] [Abstract][Full Text] [Related]
35. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.
Tarella C; Caracciolo D; Gavarotti P; Bondesan P; Cherasco C; Omedè P; Bregni M; Siena S; Gianni AM; Pileri A
Bone Marrow Transplant; 1995 Aug; 16(2):223-8. PubMed ID: 7581140
[TBL] [Abstract][Full Text] [Related]
36. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Moreau P; LeTortorec S; Mahé MA; Mahé B; Moreau A; Bourdin S; Bulabois CE; Bureau B; Harousseau JL; Milpied N
Bone Marrow Transplant; 1994 Nov; 14(5):775-8. PubMed ID: 7889011
[TBL] [Abstract][Full Text] [Related]
37. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features.
Baro J; Richard C; Calavia J; González-San Miguel JD; Bello-Fernández C; Alsar MJ; Gómez-Casares MT; Iriondo A; Conde E; Hermosa V
Bone Marrow Transplant; 1991 Oct; 8(4):283-9. PubMed ID: 1756325
[TBL] [Abstract][Full Text] [Related]
38. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
[TBL] [Abstract][Full Text] [Related]
39. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
Armitage JO; Gingrich RD; Klassen LW; Bierman PJ; Kumar PP; Weisenburger DD; Smith DM
Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847
[TBL] [Abstract][Full Text] [Related]
40. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas.
Ghalie R; Richman CM; Adler SS; Korenblit AD; Kramer TS; Manson S; Dolce A; Kaizer H
Bone Marrow Transplant; 1991 Jul; 8(1):41-5. PubMed ID: 1912954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
